High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment

Background and Purpose— This review characterizes the current state of knowledge of high-density lipoprotein (HDL) in relation to stroke. Summary of Review— HDL has anti-atherosclerotic and anti-inflammatory properties and is an important component in atherosclerosis. Serum HDL-cholesterol levels are inversely related to heart disease and stroke risk. There are various established and experimental treatments which can raise serum HDL cholesterol and improve its function. Conclusion— HDL is an emerging target for atherosclerotic stroke treatment with the potential to dramatically impact the care of stroke patients.

[1]  S. Reddy,et al.  Apolipoprotein A-I mimetic peptides , 2009, Current atherosclerosis reports.

[2]  D. Liebeskind,et al.  Achieving target cholesterol goals after stroke: is in-hospital statin initiation the key? , 2006, Archives of neurology.

[3]  H. Bloomfield.  The role of fibrates in a statin world. , 2006, Archives of internal medicine.

[4]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[5]  M. Katan.  Low HDL cholesterol levels. , 2006, The New England journal of medicine.

[6]  D. Maahs,et al.  Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  E. D. de Faria,et al.  A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. , 2005, Atherosclerosis.

[8]  Stein Harald Johnsen,et al.  Elevated High-Density Lipoprotein Cholesterol Levels Are Protective Against Plaque Progression: A Follow-Up Study of 1952 Persons With Carotid Atherosclerosis The Tromsø Study , 2005, Circulation.

[9]  D. Rader,et al.  New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport , 2005, Circulation research.

[10]  J. Berliner,et al.  A role for oxidized phospholipids in atherosclerosis. , 2005, The New England journal of medicine.

[11]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[12]  M. Kashyap,et al.  Niacin therapy in atherosclerosis , 2004, Current opinion in lipidology.

[13]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[14]  B. Psaty,et al.  Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups , 2004, Neurology.

[15]  Philippe Giral,et al.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  A. Fogelman.  When good cholesterol goes bad , 2004, Nature Medicine.

[17]  K. Yano,et al.  High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program. , 2004, American journal of epidemiology.

[18]  Paul T. Williams.  The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. , 2004, Metabolism: clinical and experimental.

[19]  P. Touboul,et al.  Stroke prevention, blood cholesterol, and statins , 2004, The Lancet Neurology.

[20]  H. Brewer,et al.  Increasing HDL Cholesterol Levels. , 2004, The New England journal of medicine.

[21]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[22]  A. Gotto,et al.  Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. , 2004, Journal of the American College of Cardiology.

[23]  J. Jamart,et al.  Lipids in ischemic stroke subtypes. , 2004, Acta neurologica Belgica.

[24]  S. Haffner.  Dyslipidemia management in adults with diabetes. , 2004, Diabetes care.

[25]  A. Ruocco,et al.  Reconstituted High-Density Lipoprotein Exhibits Neuroprotection in Two Rat Models of Stroke , 2003, Cerebrovascular Diseases.

[26]  Shirin Rahmani,et al.  Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.

[27]  J. Michael Gaziano,et al.  Cholesterol and the Risk of Ischemic Stroke , 2003, Stroke.

[28]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[29]  H. Brewer,et al.  Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. , 2003, The American journal of cardiology.

[30]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[31]  A. Weverling-Rijnsburger,et al.  High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. , 2003, Archives of internal medicine.

[32]  James W. Anderson,et al.  Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). , 2003, Diabetes care.

[33]  K. Miura,et al.  High-Density Lipoprotein Cholesterol and Risk of Stroke in Japanese Men and Women: The Oyabe Study , 2003, Stroke.

[34]  L. Chambless,et al.  Plasma Lipid Profile and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study , 2003, Stroke.

[35]  R. M. Fleming.  The effect of high-, moderate-, and low-fat diets on weight loss and cardiovascular disease risk factors. , 2002, Preventive cardiology.

[36]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[37]  S. Kaul,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.

[38]  Jan Nilsson,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.

[39]  S. Reddy,et al.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.

[40]  R. Sacco,et al.  High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. , 2001, JAMA.

[41]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[42]  S. Ebrahim,et al.  HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. , 2000, Stroke.

[43]  F. Chollet,et al.  Serum lipids in young patients with ischaemic stroke: a case-control study , 2000, Journal of neurology, neurosurgery, and psychiatry.

[44]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[45]  Y. Friedlander,et al.  Risk factors for ischemic stroke: Dubbo Study of the elderly. , 1998, Stroke.

[46]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[47]  S. Kaul,et al.  Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. , 1998, Circulation.

[48]  J. Badimón,et al.  HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[49]  D. Tanné,et al.  High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. , 1997, Stroke.

[50]  A. von Eckardstein,et al.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.

[51]  G. Boysen,et al.  Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study , 1994, BMJ.

[52]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[53]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[54]  D. Gordon,et al.  High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. , 1986, Circulation.

[55]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.